Form 8-K

8-K — ANAVEX LIFE SCIENCES CORP.

Accession: 0001731122-26-001078

Filed: 2026-08-17

Period: 2026-08-17

CIK: 0001314052

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e7862_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7862_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (e7862_ex99-2.htm)

GRAPHIC (image_001.jpg)

GRAPHIC (image_002.jpg)

GRAPHIC (ex99-2_001.jpg)

GRAPHIC (ex99-2_002.jpg)

GRAPHIC (ex99-2_003.jpg)

GRAPHIC (ex99-2_004.jpg)

GRAPHIC (ex99-2_005.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7862_8k.htm · Sequence: 1

false

0001314052

2026-08-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 17, 2026

ANAVEX

LIFE SCIENCES CORP.

(Exact name of Registrant as Specified in Its Charter)

Nevada

001-37606

98-0608404

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

630 5th Avenue, 20th Floor

New York, NY USA

10111

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area

Code: 1-844-689-3939

Check the appropriate box below if the Form 8-K filing is intended to simultaneously

satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

AVXL

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company

as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act

of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 17, 2026, Anavex Life Sciences Corp. (“Anavex”

or the “Company”) issued a press release (the “Press Release”) announcing the mailing of a letter to stockholders

(the “Stockholder Letter”) regarding the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”)

and the launch of a website, www.voteanavex.com, which contains information related to the Annual Meeting.

Copies of the Press Release and the Stockholder Letter are furnished as

Exhibits 99.1 and 99.2 to this Current Report and are incorporated herein by reference.

The information included in this Item 7.01, including

Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as

amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated

by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific

reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated August 17, 2026.

99.2

Stockholder Letter dated August 17, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANAVEX LIFE SCIENCES CORP.

Date: August 17, 2026

By:

/s/ Sandra Boenisch, CPA, CGA

Sandra Boenisch, CPA, CGA

Principal Financial Officer, Treasurer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7862_ex99-1.htm · Sequence: 2

EXHIBIT 99.1

Anavex Life Sciences Mails Letter to Stockholders

Reinforcing

Relevant Experience of All Six Director Nominees

Launches VoteAnavex.com to Provide Additional Information

on Anavex’s Director Nominees

and How to Vote at the Annual Meeting of Stockholders

NEW YORK, NY, August 17, 2026 – Anavex Life Sciences Corp. (“Anavex”

or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for

central nervous system (“CNS”) diseases with high unmet medical needs, today announced that the Executive Committee of the

Anavex Board of Directors (the “Executive Committee”) has mailed a letter to stockholders encouraging them to vote the WHITE proxy

card ”FOR” all six of Anavex’s highly qualified directors standing for election at the Company’s

2026 Annual Meeting of Stockholders (the “Annual Meeting”).

The full text of the letter being mailed to stockholders has been filed

with the U.S. Security and Exchange Commission (SEC) and is available at www.VoteAnavex.com along with voting instructions and other information

about the Annual Meeting. The letter highlights the following six highly qualified, independent director nominees and the complementary

skills and experience each nominee brings:

● Dr.

Jiong Ma, Ph.D. brings deep financial, transactional and capital markets expertise to

the Board, with substantial experience investing in, partnering with and working with management

teams to set strategy for disruptive technology and life sciences companies to shape the

business, accelerate growth and drive long-term shareholder value.

● Dr.

Peter Donhauser, D.O. brings critical, relevant experience to the Board as clinical expert

leading research across numerous trials for some of the world’s leading global pharmaceutical

companies.

●

Dr. Axel Paeger, M.D.,

MBA, MBI is a medically trained executive leader who brings deep experience in healthcare to the Board as founder of a leading

healthcare provider in Europe.

● Gautam

Patel, MBA (new independent candidate): The Executive Committee believes Mr. Patel is

qualified to serve as a member of the Board because he brings extensive capital allocation,

investment and financial advisory expertise to the Board, with a proven track record of executing

growth-focused investments and guiding corporate strategy across the life sciences, financial

services and technology sectors.

● Dr.

Adrian Senderowicz, M.D. (new independent candidate): The Executive Committee believes

Dr. Senderowicz is qualified to serve as a member of the Board because he brings deep drug

development, clinical research and global regulatory expertise to the Board, with a proven

track record of advancing novel therapeutics through critical international approvals to

drive growth and long-term value.

● Dr.

Claus van der Velden, Ph.D. brings accounting and executive financial experience to the

Board that provides critical perspective on accounting and capital allocation strategy.

The Annual Meeting will be held on September 24, 2026, and stockholders

of record as of close of business on July 31, 2026 are entitled to vote.

If you have any questions or require any assistance with voting your shares,

please call:

Innisfree M&A Incorporated

500 Fifth Avenue, 21st Floor

New York, NY 10110

Stockholders may call toll-free at (877) 750-0831

Brokers, banks and other nominees may call collect

at (212) 750-5833

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical

company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric

disorders. Further information is available at www.anavex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the

Company’s plans, strategies and expectations regarding the 2026 Annual Meeting, director nominations, the proxy solicitation, the

Company’s go-forward strategy, clinical development programs, business prospects, and potential actions of the Board and the Executive

Committee, are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the

words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,”

“may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many

factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including the risks

and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent

filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not

to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are

qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update

this press release to reflect events or circumstances after the date hereof except as required by law.

Important Additional Information and Where to Find It

The Company has filed a definitive proxy statement on Schedule 14A, an

accompanying WHITE proxy card, and other relevant documents with the SEC in connection with the solicitation of proxies from the Company’s

stockholders for the 2026 Annual Meeting. THE COMPANY’S STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE

PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD AND OTHER DOCUMENTS FILED WITH THE

SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Stockholders are able to obtain the definitive proxy statement,

any amendments or supplements to the proxy statement and other documents that the Company files with the SEC at no charge at the SEC’s

website at www.sec.gov. Copies are also available at no charge at the Company’s website at www.anavex.com.

Certain Information Regarding Participants

The Company, its directors and certain of its executive officers may be

deemed to be “participants” (as defined in Schedule 14A under the Securities Exchange Act of 1934, as amended) in the solicitation

of proxies from the Company’s stockholders in connection with the matters to be considered at the 2026 Annual Meeting. Information

regarding the names of the Company’s directors and executive officers and certain other individuals and their direct or indirect

interests in the Company, by security holdings or otherwise, is set forth in the sections entitled “Compensation of Directors,”

“Executive Compensation,” and “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Matters” of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (available here), and any

subsequent filings on Forms 3, 4 and 5 filed with the SEC. Additional information regarding the identity of potential participants, and

their direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s definitive proxy statement

for the 2026 Annual Meeting which has been filed with the SEC. These documents are available free of charge at the SEC’s website

at www.sec.gov.

Investor Relations:

SCR Partners, LLC

Alex Arzeno

Tel: 203-550-3972

Email: alex@scr-ir.com

Tripp Sullivan

Tel: 615-942-7077

Email: tsullivan@scr-ir.com

For Media:

Collected Strategies

Nick Lamplough / Dylan O’Keefe

AVXL-CS@collectedstrategies.com

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: e7862_ex99-2.htm · Sequence: 3

EXHIBIT 99.2

GRAPHIC

Filename: image_001.jpg · Sequence: 4

Binary file (3103 bytes)

Download image_001.jpg

GRAPHIC

Filename: image_002.jpg · Sequence: 5

Binary file (3936 bytes)

Download image_002.jpg

GRAPHIC

Filename: ex99-2_001.jpg · Sequence: 6

Binary file (681866 bytes)

Download ex99-2_001.jpg

GRAPHIC

Filename: ex99-2_002.jpg · Sequence: 7

Binary file (893307 bytes)

Download ex99-2_002.jpg

GRAPHIC

Filename: ex99-2_003.jpg · Sequence: 8

Binary file (837388 bytes)

Download ex99-2_003.jpg

GRAPHIC

Filename: ex99-2_004.jpg · Sequence: 9

Binary file (859579 bytes)

Download ex99-2_004.jpg

GRAPHIC

Filename: ex99-2_005.jpg · Sequence: 10

Binary file (832538 bytes)

Download ex99-2_005.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 15

v3.26.1

Cover

Aug. 17, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 17, 2026

Entity File Number

001-37606

Entity Registrant Name

ANAVEX

LIFE SCIENCES CORP.

Entity Central Index Key

0001314052

Entity Tax Identification Number

98-0608404

Entity Incorporation, State or Country Code

Entity Address, Address Line One

630 5th Avenue

Entity Address, Address Line Two

20th Floor

Entity Address, City or Town

New York

Entity Address, State or Province

Entity Address, Postal Zip Code

10111

City Area Code

844

Local Phone Number

689-3939

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

AVXL

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration